Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Arkopal Choudhury(Nektar Therapeutics (United States)), Erika Puente-Poushnejad(Nektar Therapeutics (United States)), Adi Diab(Cleveland Clinic), Ute Hoch(University of Arizona), David Chien(Nektar Therapeutics (United States)), Mehmet Asım Bilen(Emory Healthcare), Giovanni Grignani(Candiolo Cancer Institute), Mary Tagliaferri(Nektar Therapeutics (United States)), Arjun Vasant Balar(NYU Langone Health), Michael E. Hurwitz(Yale University), Daniel C. Cho(NYU Langone Health), Lily Tang(Nektar Therapeutics (United States)), Danni Yu(National Heart Lung and Blood Institute), Mario Sznol(Yale University), Sue Currie(St. Paul's Hospital), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 20
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k